David Jeans

Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom.

Part of GE Aerospace, GE UK Group is an investment holding private company. GE UK Group is based in Altrincham, UK. The British company was founded in 2008. The CEO is Kevin Michael O'Neill.

Alliance Medical Group, Inc. provides healthcare services. It offers primary care/internal medicine, pediatric, endocrinology, geriatrics, infectious disease/travel medicine, neurology, pulmonary, rheumatology, sleep medicine, surgery and weight management. The company is headquartered in Middlebury, CT.

Imanova Ltd. provides research and development solutions in biomarkers. It offers clinical imaging, preclinical imaging, analysis and consultancy, access to academic expertise, and consumer health. The company was founded in 2011 and is headquartered in London, the United Kingdom.

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.

Part of UK Biobank Ltd., UK Biocentre Ltd. operates laboratories. The private company is based in Tilbrook, UK. The British company was founded in 2011. Tony Cox has been the CEO of the company since 2020.

Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The private company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates.

Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation.